What is Prevymis used to treat?

Prevymis (letermovir) is used for the prevention of cytomegalovirus (CMV) infection in patients who have received an allogeneic stem-cell transplant (from a matching donor).

Cytomegalovirus is a potentially serious viral infection that is more common in patients who are immune-suppressed, such as AIDS patients, people with cancer, and people receiving organ or bone marrow transplants. Transplant recipients who develop CMV infection after the transplant are at increased risk for transplant failure and death.

Prevymis is a non-nucleoside CMV inhibitor that works to prevent CMV infection by inhibiting viral replication.

Prevymis is administered once daily orally, or as an intravenous (IV) infusion over 1 hour, for 100 days post-transplant.

Common side effects include nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.